San Francisco, California, September 28, 2018 – The evolution of the whole exome sequencing market is driven by the constant advances made in targeted sequencing technologies. This is increasingly reinforced by rapid advances in genomics in recent years. The substantial reduction in cost and sequencing space is stoking the popularity of whole exome sequencing over whole genome sequencing across the globe.
An in-depth evaluation of the above trends and more and their impact on the prospects of the whole genome sequencing market are covered in a report by TMR Research. The study is titled “Whole Exome Sequencing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”.
Get Sample Copy of this Report @
The crucial role that whole exome sequencing plays in identifying possible disease-causing mutations is a key factor supporting the rapid expansion of the market. The rising demand for next-generation sequencing technologies for monitoring pathogenic infections and cancer with the help of is fueling the demand for whole exome sequencing.
The growing adoption of whole exome sequencing services and systems among researchers is attributed to their affordability. This is also true of human genomes. However, the disproportionate improvement in the storage and analysis technology serves as a bottleneck to the adoption of whole exome sequencing. Nevertheless, constant improvements in exome capture platforms is creating promising avenues in the market.
The extensive demand for whole exome sequencing for finding novel causative mutations for known disease phenotypes as well for difficult-to-diagnose diseases has accentuated the market in recent years. The benefits of accurate prognoses and confirmed diagnoses offered by whole exome sequencing makes it particularly promising for clinical trials, world over. The growing demand for early diagnosis for a range of debilitating diseases is also likely to bolster the application of whole exome sequencing platforms.
Read Comprehensive Overview of Report @
Some of the key players operating in the global whole exome sequencing market are Sengenics, Roche NimbleGen Inc., Illumina Inc., Ambry Genetics, Macrogen Inc., Eurofins Genomics, and Agilent Technologies.